Everson Richard G, Antonios Joseph P, Liau Linda M
Prog Neurol Surg. 2018;32:90-100. doi: 10.1159/000469683. Epub 2018 Jul 10.
Current cell-based immunotherapeutic strategies attempt to produce and maintain an immune response against glioma cells by artificially stimulating the immune system using passive and/or active approaches. Cellular immunotherapy is taken to mean the administration of live immune cells that either have immune effector capabilities themselves (passive immunotherapy) or engender a downstream antitumor response (active immunotherapy). Passive cellular immunotherapy most often takes the form of the adoptive transfer of a range of cell types, whereby antitumor immune cells from a patient (or allogeneic donor) are created, activated, and/or expanded ex vivo and subsequently administered back to the patient to directly attack the neoplasm. Active cellular immunotherapy approaches for the treatment of malignant gliomas have most often taken the form of dendritic cell (DC)-based vaccines.
当前基于细胞的免疫治疗策略试图通过被动和/或主动方法人工刺激免疫系统，以产生并维持针对胶质瘤细胞的免疫反应。细胞免疫疗法是指给予具有免疫效应能力（被动免疫疗法）或引发下游抗肿瘤反应（主动免疫疗法）的活免疫细胞。被动细胞免疫疗法最常见的形式是一系列细胞类型的过继性转移，即从患者（或同种异体供体）中获取抗肿瘤免疫细胞，在体外进行产生、激活和/或扩增，随后再回输到患者体内以直接攻击肿瘤。治疗恶性胶质瘤的主动细胞免疫疗法最常见的形式是基于树突状细胞（DC）的疫苗。
